A surgical gown is classified by the U.S. Food Drug and Administration (FDA) as a Class II medical device that requires 510(k) premarket notification. Surgical gowns can be used for any risk level (Levels 1-4) such as Level 1: Used for minimal risk situations, during basic care, or in a standard medical unit; Level 2: Used in low risk situations such as drawing blood, suturing, or in a pathology lab; Level 3: Used in moderate risk situations, for inserting an intravenous (IV) line, emergency room, or for trauma cases; Level 4: Used in high risk situations such as for pathogen resistance or non- airborne diseases, and infectious diseases.
The Eastern Europe surgical drapes and gowns market size is estimated to be valued at US$ 55.27 million in 2020 and is expected to exhibit a CAGR of 3.8% over the forecast period (2020-2027).
Figure 1. Eastern Europe Surgical Drapes and Gowns Market Value (US$ Mn), 2016-2027
The rising number of hospital acquired infections (HAI) during hospitalization due to exposure of patients to pathogens through different sources such as hospital environment, and other infected patients is one of the key factors that is expected to drive growth of the Eastern Europe surgical drapes and gowns market over the forecast period. For instance, according to the annual epidemiological report for surgical site infections, published by the European Centre for Disease Prevention and Control, in 2016, stated that the rate of surgical site infections (SSIs) after coronary artery bypass graft operations, cholecystectomy operations, caesarean sections, and colon surgery was 3.4%, 1.7%, 1.4%, and 13.2%, respectively.
Furthermore, increasing number of surgical procedures, owing to rising incidence of chronic and infectious diseases and medical emergencies such as cardiac cases and sudden trauma are the major factors contributing to the growth of the Eastern Europe surgical drapes and gowns market. For instance, according to the annual epidemiological report for surgical site infections 2016, published by European Centre for Disease Prevention and Control, the number of surgeries performed in the Hungary was around 9,094 in the year 2016.
|Base Year:||2019||Market Size in 2020:||US$ 55.27 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||3.8%||2027 Value Projection:||US$ 71.7 Mn|
Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
|Restraints & Challenges:||
Eastern Europe Surgical Drapes and Gowns Market – Impact of Coronavirus (Covid-19)
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in over 50.9 million infected individuals worldwide as of November 11, 2020.
Moreover, increasing spread of the novel coronavirus has hampered growth of the Eastern Europe surgical drapes and gowns market. For instance, In March 2020, the World Health Organization (WHO) declared COVID-19 as an Eastern Europe pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic slowed down growth of the healthcare sector and led to a disturbance in the supply chain
Figure 2. Eastern Europe Surgical Drapes and Gowns Market Share (%), by Region, 2020
Among countries, Russia is expected to hold dominant position in the Eastern Europe surgical drapes and gowns market during the forecast period, owing to increasing number of surgical procedures in the country. For instance, according to an article published in the National Center for Biotechnology Information (NCBI) February 2017, around 75,378 per-cutaneous coronary intervention (PCI) and around 101,451 stent placements procedures were performed in 175 Russian percutaneous coronary intervention (PCI) Centers.
Major players operating in the Eastern Europe surgical drapes and gowns market include 3M, Halyard Health, Inc., Thermo Fisher Scientific Inc, Steril Medical, Molnlycke Healthcare AB, Cardinal Health, Inc, Medica Europe BV, Priontex, Paul Hartmann AG, Guardian Surgical, Alpha Pro Tech, Ltd, Anhui Medpurest Medical Technology Co., Ltd, Lohmann & Rauscher International GmbH & Co. KG, Vygon S.A, Medline Industries, Inc, Garmex Medical Textiles, TIDI Products, LLC, Stryker Corporation, Teleflex Incorporated, Surgeine Healthcare (India) Private Limited, and Amaryllis Healthcare Private Limited.
Surgical drapes are used during surgery to maintain sterility in the surgical environment, equipment, and the patient’s surroundings. There are several procedures (almost all types of invasive procedures), where surgical drapes are required. These procedures include cardiovascular procedures, general procedures, orthopedic procedures, ophthalmic procedures, gynecology procedures, and others. Various healthcare companies such as Thermo Fisher Scientific, 3M, Halyard Health, Mercator Medical S.A., MediPorta Ltd., MediPorta Ltd., and others offer surgical drapes in the Eastern Europe market. Similar to surgical drapes, surgical gowns are a necessity in the operation theater for facilitating a sterile environment, while carrying invasive procedures.
Key players are focused on adopting different business strategies such as product launches and advancements to expand their offerings in Eastern Europe surgical drapes and gowns market. For instance, in 2018, JB Rosenthal Enterprises, launched a disposable patient protector drape for use during vaginal labor & deliveries, gynecological, and urological surgeries. The drape provides a barrier of protection for doctors, patients, and newborn babies that helps to reduce the possibility of infection from fecal matter of newborns.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.